A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Conditions

Moderate-to-severe Allergic Asthma

Brief summary

This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up. Approximately 60 participants will be enrolled, and omalizumab will be dosed according to the approved United States Package Insert (USPI) dosing table.

Related papers

No related papers found yet.

Interventions

DRUGOmalizumab

Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

No

Inclusion criteria

* Physician-diagnosed asthma for at least 12 months prior to screening * Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen * Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period * Able to safely complete incremental exercise tolerance at screening * Pre-bronchodilator FEV1 of 40%-80% of predicted at screening * Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry * On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (≥)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for ≥3 months prior to screening * Uncontrolled asthma during the screening period, defined as an ACQ-5 ≥0.75 score * Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug.

Exclusion criteria

* Known history of anaphylaxis/hypersensitivity to omalizumab * Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening * Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening * Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period * Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period * Isolated diagnosis of exercise induced asthma without chronic symptoms * History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma * Current malignancy or history of malignancy within 5 years prior to screening * Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions * Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening * Current smoker or past smoker with \>10 pack years * Known HIV infection at screening * Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening * Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening * Active tuberculosis requiring treatment within 12 months prior to screening * History of alcohol, drug, or chemical abuse within 6 months of screening

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline at Week 24 in Endurance Time (Minutes) During Cardiopulmonary Exercise Testing (CPET) at a Constant Work Rate (CWR)	From Baseline to Week 24	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.

Secondary

Measure	Time frame	Description
Change From Baseline at Week 24 in Dynamic Hyperinflation at Isotime, as Measured by Inspiratory Capacity During CPET at a CWR	From Baseline to Week 24	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
Change From Baseline at Week 24 in Sleep Efficiency as Assessed by a Wearable Physical Activity and Sleep Monitor	From Baseline to Week 24	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
Change From Baseline at Week 24 in Physical Activity (Minutes/Day) as Assessed by a Wearable Physical Activity and Sleep Monitor	From Baseline to Week 24	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
Percentage of Participants With Serious Adverse Events	From Baseline to Week 28	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
Percentage of Participants With Adverse Events Leading to Discontinuation of Omalizumab	From Baseline to Week 24	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
Percentage of Participants With Adverse Events	From Baseline to Week 28	This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.

Countries

United States

Participant flow

Pre-assignment details

This study was terminated by the Sponsor. Only 3 participants were enrolled in this study.

Participants by arm

Arm	Count
Omalizumab Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.	0
Total	0

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 3
other Total, other adverse events	2 / 3
serious Total, serious adverse events	0 / 3